Daratumumab or Darzalex Market 2026 expanding with multiple myeloma therapies

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Daratumumab Or Darzalex Market During The Forecast Period 2026–2030?

The market size for daratumumab or darzalex has experienced significant expansion in recent years. Projections indicate its growth from $5618.3 million in 2025 to $6189.36 million in 2026, demonstrating a compound annual growth rate (CAGR) of 10.2%. Historically, this growth can be attributed to factors such as its authorization for multiple myeloma treatment, impressive clinical results when targeting CD38, a scarcity of alternative treatments for relapsed conditions, widespread adoption by oncology centers, and improved patient survival rates.

The daratumumab or darzalex market size is anticipated to undergo significant expansion over the next few years. It is predicted to reach $9024.5 million by 2030, exhibiting a compound annual growth rate (CAGR) of 9.9%. This projected growth during the forecast period is attributable to the wider adoption of combination regimens, the increasing prevalence of multiple myeloma, heightened investment in oncology, the introduction of new indications, and enhanced patient access programs. Prominent trends for the forecast period include its increasing acceptance in treating multiple myeloma, its use in combination with other oncology drugs, its integration into earlier treatment stages, hospital-based administration of monoclonal antibody therapy, and its expanding application in various hematologic malignancies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19896&type=smp

What Drivers Are Expected To Influence The Daratumumab Or Darzalex Market During The Forecast Period?

The daratumumab or darzalex market is anticipated to expand due to an increasing occurrence of bone marrow cancer. Bone marrow cancer encompasses malignancies originating in the bone marrow, such as multiple myeloma and leukemia, where irregular blood cell formation disrupts typical bodily functions. This growing prevalence of bone marrow cancers stems from factors like an aging demographic, enhanced diagnostic techniques, and other elements such as environmental exposure, lifestyle decisions, and genetic susceptibility. Daratumumab (Darzalex) aids in managing multiple myeloma, a form of bone marrow cancer, by specifically targeting and eliminating aberrant plasma cells within the bone marrow. For example, the American Cancer Society, a US-based non-profit entity, projected in January 2025 that the year 2025 would see roughly 3,770 new instances of primary bone and joint cancer (2,150 in men and 1,620 in women), alongside an estimated 2,190 fatalities (1,240 in men and 950 in women). Consequently, the increasing incidence of bone marrow cancer is fueling the expansion of the daratumumab or darzalex market.

What Market Segments Are Evaluated Within The Daratumumab Or Darzalex Market?

The daratumumab or darzalex market covered in this report is segmented –

1) By Drug Type: 100Mg Injection, 400Mg Injection

2) By Distribution Channel: Pharmacies, Hospital, Other Distribution Channels

3) By Application: Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Diffuse Large B Cell Lymphoma, Other Applications

What Industry Trends Are Redefining The Daratumumab Or Darzalex Market?

Leading firms within the daratumumab or darzalex market are increasingly directing their attention toward transforming oncology care through early intervention methods, particularly combination therapies, aimed at improving the effectiveness against multiple myeloma and various other cancers. These combination therapies involve treatment approaches employing multiple therapeutic agents with distinct operational mechanisms, frequently working synergistically, to boost effectiveness, mitigate resistance, and enhance patient results, while potentially lowering side effects compared to single-agent treatments. An illustrative example is from July 2024, when Johnson & Johnson, a US-based pharmaceutical industry company, secured U.S. FDA approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) combined with bortezomib, lenalidomide, and dexamethasone (D-VRd). This approval is for induction and consolidation therapy in individuals diagnosed with newly diagnosed multiple myeloma (NDMM) who are candidates for autologous stem cell transplant (ASCT). This recent authorization introduces a quadruplet therapy choice available at the initial diagnosis stage, which could potentially better patient outcomes.

Who Are The Top Market Participants Influencing The Daratumumab Or Darzalex Market?

Major companies operating in the daratumumab or darzalex market are Genmab A/S, Janssen Biotech Inc.

Read the full daratumumab or darzalex market report here:

https://www.thebusinessresearchcompany.com/report/daratumumab-or-darzalex-global-market-report

Which Region Is Forecast To Lead The Daratumumab Or Darzalex Market In Terms Of Market Size?

North America was the largest region in the daratumumab or darzalex market in 2025. The regions covered in the daratumumab or darzalex market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Daratumumab Or Darzalex Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19896&type=smp

Browse Through More Reports Similar to the Global Daratumumab Or Darzalex Market 2026, By The Business Research Company

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Rheumatoid Arthritis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/rheumatoid-arthritis-drugs-global-market-report

Sarcoma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/sarcoma-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795